In 2019, the Food and Drug Administration (FDA) approved the first antibody-drug conjugate (ADC) targeting Nectin-4, known as enfortumab vedotin (EV), for treating urothelial carcinoma. The gene discussed is NECTIN4; the disease is urothelial carcinoma.